Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators?
Open accessThe DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index; 13 of the 168 sources its claims cite were checked for support.
Abstract
Despite decades of basic and clinical research, our understanding of how benzodiazepines tend to lose their efficacy over time (tolerance) is at least incomplete. In appears that tolerance develops relatively quickly for the sedative and anticonvulsant actions of benzodiazepines, whereas tolerance to anxiolytic and amnesic effects probably does not develop at all. In light of this evidence, we review the current evidence for the neuroadaptive mechanisms underlying benzodiazepine tolerance, including changes of (i) the receptor (subunit expression and receptor coupling), (ii) intracellular changes stemming from transcriptional and neurotrophic factors, (iii) ionotropic glutamate receptors, (iv) other neurotransmitters (serotonin, dopamine, and acetylcholine systems), and (v) the neurosteroid system. From the large variance in the studies, it appears that either different (simultaneous) tolerance mechanisms occur depending on the benzodiazepine effect, or that the tolerance-inducing mechanism depends on the activated receptor subtypes. Importantly, there is no convincing evidence that tolerance occurs with α subunit subtype-selective compounds acting at the benzodiazepine site.
Overview
CoChat Summary
TL;DR
This review synthesizes evidence on neuroadaptive mechanisms of benzodiazepine tolerance, concluding that tolerance develops relatively quickly for sedative/hypnotic and anticonvulsant effects but probably not for anxiolytic and amnesic effects. It finds no convincing evidence that α subunit subtype-selective compounds acting at the benzodiazepine site produce tolerance comparable to classical benzodiazepines.
Key findings
- Tolerance is effect-specific: it develops rapidly for sedative/hypnotic and anticonvulsant actions, whereas tolerance to anxiolytic and amnesic effects most probably does not develop at all. Anticonvulsant tolerance develops during the first several months in 30–50% of epilepsy patients treated with clobazam or clonazepam.
- Proposed mechanisms include GABA_A receptor uncoupling, altered subunit expression, ionotropic glutamate receptor changes, transcriptional/neurotrophic factors, serotonin/dopamine/acetylcholine systems, and neurosteroids; none sufficiently explains tolerance, and the literature is heterogeneous. α5 subunits comprise 15–20% of diazepam-sensitive GABA_A receptors, and α5 together with α1 subunits has been implicated in tolerance to diazepam’s sedative action.
- Subtype-selective α2/α3 compounds show little tolerance in reviewed studies: no tolerance to acute hypothermic, anxiolytic, or sedative effects of diazepam in mice treated for 28 days with TPA023 (unpublished data), no analgesic tolerance after 9-day L838,417 in rats, and no sedative/anticonvulsant tolerance with chronic zolpidem but not midazolam in mice and rats. TPA023 has 0% α1 intrinsic activity versus 23% for TPA123; TPA123 led to benzodiazepine-like reinforcement and withdrawal, whereas TPA023 did not.
- Clinical anxiolytic tolerance was not observed in a double-blind study of 180 chronically anxious outpatients given diazepam 15–40 mg/day for 6–22 weeks, nor after 8 weeks of alprazolam in panic disorder with continued efficacy.
Methods
- Narrative review of basic and clinical literature; no primary experiments or systematic search/meta-analysis are described.
- It reviews evidence on GABA_A receptor subunit expression and coupling, intracellular/transcriptional and neurotrophic factors, ionotropic glutamate receptors, serotonin/dopamine/acetylcholine systems, neurosteroids, and subtype-selective GABA_A receptor modulators.
- Evidence includes preclinical rodent and nonhuman primate studies and clinical studies in insomnia, epilepsy, panic disorder, generalized anxiety disorder, social phobia, and healthy volunteers.
Limitations
- The authors state that understanding of tolerance remains incomplete; studies show large variance due to different methodologies, species, treatment regimens, and benzodiazepines; classical benzodiazepines are treated as a homogeneous class, which may complicate interpretation; molecular results are often not combined with behavioral tests; clinical in vivo binding or postmortem GABA_A receptor expression studies are lacking; no studies directly investigate GABA_A receptor subunit composition after chronic exposure; preclinical tolerance is often not directly related to dose, dosing interval, plasma levels, or half-life; and many studies have relatively short exposure durations.
- Evident from the text: this is a narrative review without a described systematic search or formal quality appraisal, and some key claims about subtype-selective compounds rely on unpublished data from the authors’ laboratory.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 GABAA receptor trafficking and associated proteins. GABAA receptors are assembled from individual subunits in the endoplasmatic reticulum (ER) where the chaperones BiP and Calnexin assist in quality control. Unassembled GABAA receptor subunits that are to be targeted for ER-associated degradation are ubiquitinated and degraded in the proteasome. The ubiquitin-like protein PLIC can interact with GABAA receptors thereby inhibiting their targeting for proteasomal degradation. Assembled pentameric GABAA receptors exit the ER and bind the guanidine exchange factor brefeldin-A-inhibited GDP/GTP exchange factor 2 (BIG2) in the Golgi. Here they also interact with the palmitoylase transferase GODZ and Gamma-aminobutyric acid receptor-associated protein (GABARAP). GABARAP interacts with the NEM sensitive fusion (NSF) protein, as does the GABAA receptor β subunit, and this association may facilitate transport of the receptor complexes to the cell surface. GABAA receptors are inserted at extrasynaptic sites and can diffuse along the plasma membrane in and out of synaptic domains. At synapses they are stabilized by an interaction with the scaffolding protein Gephyrin. The interaction of the GABAA receptor intracellular loops with the μ2 subunit of the adaptin complex AP2 is important for GABAA receptor internalization. GABAA receptors are delivered by a clathrin-mediated pathway to early endosomes where they can be targeted for degradation in the lysosome or for recycling upon binding of Huntington-associated protein (HAP1). Reprinted by permission from Elsevier, reprinted from [101].](https://figures.cochat.ai/paper-figures/44dde951ad1a4298b3801d9931725bcb/mechanisms-underlying-tolerance-after-long-term-benzodiazepine-use-a-future-for-figure-2.jpg)
![Figure 3 Functional crosstalk between G-protein coupled receptors (GPCRs) (which are present in the serotonin, dopamine, acetylcholine system) and GABAA receptors is facilitated through multiple protein kinases and scaffold proteins. GABAA receptor β and γ2 subunits are phosphorylated (P) by PKA and PKC upon the activation of individual GPCRs for dopamine and serotonin. PKA phosphorylation of GABAA receptor β1 and β3 subunits is dependent upon AKAP150/79, which directly interacts with these receptor subunits. AKAP150/79 also binds inactive PKA composed of regulatory (R) and catalytic (C) subunits. In addition, PKC phosphorylates the receptor β1–3 and γ2 subunits. Upon the activation of the appropriate GPCR, PKC-mediated phosphorylation is facilitated by the direct (but independent) interaction of the receptor for activated C kinase (RACK-1) and the β isoform of PKC with the GABAA receptor β1–3 subunits. RACK-1 facilitates functional regulation of GABAA receptors by controlling the activity of PKC associated with these proteins. The GABAA receptor γ2 subunit is also phosphorylated by Src, and this kinase is capable of binding to receptor β and γ2 subunits. Finally, the functional effects of phosphorylation are diverse and range from inhibitions to enhancements of GABAA receptor activity, dependent upon the receptor subunit composition. Reprinted by permission from Elsevier, reprinted from [95].](https://figures.cochat.ai/paper-figures/5ff87939f822496fafdeb2e73768c0b0/mechanisms-underlying-tolerance-after-long-term-benzodiazepine-use-a-future-for-figure-3.jpg)
Verification
Claims the paper makes
7 Valid · 4 Not valid · 97 Not checked · 61 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, the uncoupling process is an aspecific process as it can be induced by exposure to different classes of GABAA receptor modulators acting at different modulatory sites, such as neurosteroids and barbiturates [82].”
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > 4. Mechanisms Underlying Tolerance > 4.2. GABAA System Hypotheses
What the sources say
- Disputedcites [82] Friedman LK Gibbs TT Farb DH γ-aminobutyric acidA receptor regulation: heterologous uncoupling of modulatory site interactions induced by chronic steroid, barbiturate, benzodiazepine, or GABA treatment in culture Brain Research 1996 707 1 100 109 8866718 sourceExperimental — accuracy not yet measured
The Discussion (Section 4) of Friedman et al. (1996) does state that allosteric uncoupling can be induced by 'a variety of GABAAR modulators of different classes, acting at different sites', which supports the illustrative half of the claim, but it frames this only as raising 'the question of the specificity of uncoupling' and then explicitly rejects the aspecific reading: 'The results are also inconsistent with the chronic treatment drug non-specific model, because different chronic drug treatments produced different patterns of uncoupling,' concluding there are at minimum two distinct ways coupling can be modified and, in the Introduction, that 'there may be multiple modes of uncoupling, and ... multiple mechanisms of uncoupling.' Thus the paper contradicts rather than supports the assertion that uncoupling is an aspecific process; the abstract likewise calls it 'Surprising' that different chronic treatments produce different patterns. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In support, BDNF (and NT-4) was found to acutely reduce postsynaptic GABAA receptor immunoreactivity via activation of TrkB receptors [135–139]”
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > 4. Mechanisms Underlying Tolerance > 4.4. Other Mechanisms
What the sources say
- Not checked yetcites [135] Brunig I Penschuck S Berninger B Benson J Fritschy JM BDNF reduces miniature inhibitory postsynaptic currents by rapid downregulation of GABAA receptor surface expression European Journal of Neuroscience 2001 13 7 1320 1328 11298792 source
- Disputedcites [136] Jovanovic JN Thomas P Kittler JT Smart TG Moss SJ Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABAA receptor phosphorylation, activity, and cell-surface stability Journal of Neuroscience 2004 24 2 522 530 14724252 PMC6729993 sourceExperimental — accuracy not yet measured
In “Biphasic temporal modulation of GABAₐR-β3 phosphorylation by BDNF” (page unavailable), the paper reports that BDNF increased—not reduced—cell-surface GABAₐ receptors within 10 minutes; a TrkB inhibitor prevented the increase in surface β3 subunits. These measurements are of cell-surface levels rather than specifically postsynaptic immunoreactivity, and the cited passages provide no NT-4 result. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [137] Tanaka T Saito H Matsuki N Inhibition of GABAA synaptic responses by brain-derived neurotrophic factor (BDNF) in rat hippocampus Journal of Neuroscience 1997 17 9 2959 2966 9096132 PMC6573653 sourceExperimental — accuracy not yet measured
The Abstract reports that BDNF reduced GABAA-mediated responses within five minutes, and “Involvement of postsynaptic TrkB activation” links the reduction in IPSCs to a postsynaptic Trk-type receptor (page numbers unavailable). The paper measures synaptic currents and responses to applied GABA, not postsynaptic GABAA receptor immunoreactivity; it also does not report this effect for NT-4. (LLM, conf=0.90)
- Partly supportedcites [138] Cheng Q Yeh HH Brain-derived neurotrophic factor attenuates mouse cerebellar granule cell GABAA receptor-mediated responses via postsynaptic mechanisms Journal of Physiology 2003 548 3 711 721 12640011 PMC2342883 sourceExperimental — accuracy not yet measured
The Results report that acute BDNF exposure reduced GABAA receptor β2/3 immunoreactivity in cultured cerebellar granule cells, and that K252a prevented the reduction. The Discussion links BDNF's effects to TrkB signalling, but says NT-4/5's possible attenuation of GABA responses in these cells awaited experimentation; it does not report an NT-4/5 reduction in receptor immunoreactivity. Page numbers were not provided in the supplied passages. (LLM, conf=0.90)
- Not checked yetcites [139] Henneberger C Jüttner R Rothe T Grantyn R Postsynaptic action of BDNF on GABAergic synaptic transmission in the superficial layers of the mouse superior colliculus Journal of Neurophysiology 2002 88 2 595 603 12163512 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“One study using α subunit point mutation mice implicated a critical role for α 5 subunits together with α 1 subunits in the decreasing sedative efficacy of the classical benzodiazepine diazepam after chronic treatment [27].”
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > 2. Benzodiazepines and the GABAA System > 2.2. Benzodiazepines from a Nonspecific towards a Subunit-Specific Pharmacology
What the sources say
- Supportedcites [27] van Rijnsoever C Täuber M Choulli MK Requirement of α5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice Journal of Neuroscience 2004 24 30 6785 6790 15282283 PMC6729721 source
The Abstract and the section 'Tolerance to the sedative action of diazepam in point-mutated mice' describe the histidine-to-arginine α-subunit point-mutation knock-in mice (α1, α2, α3, α5) chronically treated with diazepam, where α5(H105R) mice failed to display any sedative tolerance while wild-type, α2 and α3 mice did. The Discussion states that 'α1- and α5-GABAA receptors appear to be the specific molecular substrates contributing in a competitive manner to the chronic effects of diazepam on motor activity,' with α5 interaction essential for the behavioral manifestation of tolerance, and the concluding paragraph proposes tolerance depends on two mechanisms orchestrated by α1- and α5-GABAA receptors. This matches the claim's attribution of a critical joint α5/α1 role in the diminished sedative efficacy of diazepam after chronic treatment. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Using self-administration studies, it was shown that efficacy at α 1-containing GABAA subtypes significantly contributed to the reinforcing effects and withdrawal symptoms of benzodiazepines [8, 28, 29].”
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > 2. Benzodiazepines and the GABAA System > 2.2. Benzodiazepines from a Nonspecific towards a Subunit-Specific Pharmacology
What the sources say
- Partly supportedcites [8] Ator NA Atack JR Hargreaves RJ Burns HD Dawson GR Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at α 1 and α 2/3 subtypes Journal of Pharmacology and Experimental Therapeutics 2010 332 1 4 16 19789360 PMC2802472 sourceExperimental — accuracy not yet measured
Our copy does link self-administration findings to an α1 role in reinforcement, but only tentatively and partly in retreat: the Mechanisms section says 'It initially seemed to us (Ator, 2005) that the α1 subtype must play a prominent role in mediating reinforcing effects' based on high zolpidem/zaleplon self-administration rates, yet immediately notes L-838,417 has no α1 efficacy but maintained self-administration, concluding only that 'elimination of α1 efficacy may play a role' while 'reduction of efficacy at α2/α3 subtypes below 35% may be the critical element', and stating 'It is not possible to discriminate which of these factors is primarily responsible for the reinforcing efficacy.' The withdrawal/dependence part is not attributed to α1: the Physiological Dependence section merely records that chronic administration of nonselective and α1-selective full agonists produced dependence signs, and the Implications paragraph leaves open whether reduced dependence potential reflects 'no α1 efficacy and/or reduced α2/α3 efficacy'. So the claim's confident causal attribution to α1 for both reinforcement and withdrawal overstates this source. (LLM, conf=0.75)
- Not checked yetcites [28] Ator NA Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders CNS Spectrums 2005 10 1 31 39 15618945 source
- Not checked yetcites [29] Griffiths RR Sannerud CA Ator NA Brady JV Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal Journal of Pharmacology and Experimental Therapeutics 1992 260 3 1199 1208 1312162 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Also, more recent indications for reduced allosteric coupling were found after chronic treatment using transfected cell lines that express GABAA receptors or in neurons [84–94].”
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > 4. Mechanisms Underlying Tolerance > 4.2. GABAA System Hypotheses
What the sources say
- Not checked yetcites [84] Wong G Lyon T Skolnick P Chronic exposure to benzodiazepine receptor ligands uncouples the γ—aminobutyric acid type A receptor in WSS-1 cells Molecular Pharmacology 1994 46 6 1056 1062 7808424 source
- Not checked yetcites [85] Tietz EI Chiu TH Rosenberg HC Regional GABA/benzodiazepine receptor/chloride channel coupling after acute and chronic benzodiazepine treatment European Journal of Pharmacology 1989 167 1 57 65 2476326 source
- Not checked yetcites [86] Primus RJ Yu J Xu J Allosteric uncoupling after chronic benzodiazepine exposure of recombinant γ-aminobutyric acidA receptors expressed in Sf9 cells: ligand efficacy and subtype selectivity Journal of Pharmacology and Experimental Therapeutics 1996 276 3 882 890 8786565 source
- Not checked yetcites [87] Pericic D Strac DS Jembrek MJ Vlainic J Allosteric uncoupling and up-regulation of benzodiazepine and GABA recognition sites following chronic diazepam treatment of HEK 293 cells stably transfected with α1β2γ2S subunits of GABAA receptors Naunyn-Schmiedeberg’s Archives of Pharmacology 2007 375 3 177 187 17377772 source
- Supportedcites [88] Klein RL Harris RA Regulation of GABAA receptor structure and function by chronic drug treatments in vivo and with stably transfected cells Japanese Journal of Pharmacology 1996 70 1 1 15 8822084 source
The Results from drug treatments (p. 8) report reduced coupling between GABA and benzodiazepine binding sites after treatment of stably transfected PA3 cells, and compare the finding with uncoupling in neurons. The Conclusions from the stably transfected cells (p. 9) likewise state that chronic-treatment effects on allosteric coupling observed in neurons can be observed in stably transfected cells. (LLM, conf=0.94)
- Not checked yetcites [89] Klein RL Mascia MP Harkness PC Hadingham KL Whiting PJ Harris RA Regulation of allosteric coupling and function of stably expressed γ-aminobutyric acid GABAA receptors by chronic treatment with GABAA and benzodiazepine agonists Journal of Pharmacology and Experimental Therapeutics 1995 274 3 1484 1492 7562525 source
- Not checked yetcites [90] Ali NJ Olsen RW Chronic benzodiazepine treatment of cells expressing recombinant GABAA receptors uncouples allosteric binding: studies on possible mechanisms Journal of Neurochemistry 2001 79 5 1100 1108 11739624 source
- Not checked yetcites [91] Itier V Granger P Perrault G Depoortere H Scatton B Avenet P Protracted treatment with diazepam reduces benzodiazepine1 receptor-mediated potentiation of gamma-aminobutyric acid-induced currents in dissociated rat hippocampal neurons Journal of Pharmacology and Experimental Therapeutics 1996 279 3 1092 1099 8968329 source
- Not checked yetcites [92] Heninger C Gallager DW Altered γ-aminobutyric acid/benzodiazepine interaction after chronic diazepam exposure Neuropharmacology 1988 27 10 1073 1076 2853312 source
- Supportedcites [93] Brett RR Pratt JA Changes in benzodiazepine-GABA receptor coupling in an accumbens-habenula circuit after chronic diazepam treatment British Journal of Pharmacology 1995 116 5 2375 2384 8581272 PMC1909033 source
The GABAA receptor discussion reports reduced benzodiazepine–GABA coupling in several rat brain regions after chronic diazepam treatment, including the nucleus accumbens and lateral habenula. This supports the neuronal-circuit part of the cited statement; the paper used brain-section autoradiography, not transfected cell lines. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
96 more claims · 1 with their cited sources checked
Create a free account to see all 169 claims and to verify the 155 references still open.
- It may state two separate claims as one. 53
- Probably not a substantial claim. 23
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This guidance reflects the general lack of evidence for the long-term clinical benefit of BZDs, as well as research demonstrating that the clinical benefits may decrease over time while the risks persist.32–34”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > 3. The Development of Benzodiazepine Tolerance > 3.2. Clinical Studies on Anticonvulsant Tolerance
“Chronic treatment in rodents with the α 1-preferential compound CL218, 572 resulted in loss of picrotoxin-induced seizures [58].”
§ Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators? > References
“58. File SE Wilks L Effects of acute and chronic treatment on the pro- and anti-convulsant actions of CL 218, 872, PK 8165 and PK 9084, putative ligands for the benzodiazepine receptor Journal of Pharmacy and Pharmacology 1985 37 4 252 256 2860223”
Citations
Cites
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 1×
“Three classes of the ionotropic glutamate receptor occur in het central nervous system: the NMDA receptor (N-methyl-D-aspartate), the AMPA receptor (alpha-amino-3-hydroxy-5-methyl-4isoxazole-4-propionic acid), and the kainate receptor (for a recent review see [113]).”
BackgroundSynchronization of neuronal activity in hippocampus by individual GABAergic interneurons
Cobb, S. R., Buhl, E. H., Halasy, K., Paulsen, O., & Somogyi, P. (1995) · Nature · doi:10.1038/378075a0 · Cited by 1,498 · cited 1×
“Indeed, increasing knowledge on the specific functions of different GABAA receptor subunits has led to a breakthrough of novel and more selective drugs acting at the benzodiazepine site of the GABAA receptor.”
BackgroundThe yin and yang of neurotrophin action
Lu, B., Pang, P. T., & Woo, N. H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1726 · Cited by 1,356 · cited 1×
“Neurotrophic proteins support neuronal survival, synaptic growth, and differentiation throughout the brain via tyrosine kinase receptors (Trk) and, with lower affinity, via p75 receptors (p75NTRs) [134].”
BackgroundStructure and pharmacology of gamma-aminobutyric acidA receptor subtypes.
Sieghart, W. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06840-1 · Cited by 1,301
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“In support, close neuroanatomical connections exist between GABAergic and glutamatergic neurons [108, 109].”
BackgroundWhich GABAA-receptor subtypes really occur in the brain?
McKernan, R. M., & Whiting, P. J. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)80023-3 · Cited by 1,222
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172 · cited 1×
“Both genetic and pharmacological approaches explored the hypothesis that α subunits differentially contribute to the different effects of classical benzodiazepines The genetic approach consisted of point mutations into specific α subunits (α1(H101R), α2(H101R), α3(H126R), and α5(H105R)), turning them functionally inse…”
BackgroundMcKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944 · cited 2×
“Specifically, α1-containing GABAA receptors probably mediate the sedative, amnesic, and anticonvulsant actions of classical benzodiazepines [13, 23].”
BackgroundSubunit Composition, Distribution and Function of GABA-A Receptor Subtypes
Sieghart, W., & Sperk, G. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023393507 · Cited by 914 · cited 2×
“α5 subunits are predominantly expressed in the hippocampus where they comprise 15–20% of the diazepam-sensitive GABAA receptors [16].”
BackgroundNMDA receptor subunits: function and pharmacology
PAOLETTI, P., & NEYTON, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.011 · Cited by 887
A new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716 · cited 1×
“Table 1: Localization of common GABAA receptor subtypes in the brain (adapted from [19]).”
BackgroundGABAA receptor trafficking and its role in the dynamic modulation of neuronal inhibition
Jacob, T. C., Moss, S. J., & Jurd, R. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2370 · Cited by 695
Collinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628 · cited 1×
“In contrast, muscle relaxation and anxiety reduction after benzodiazepine administration was primarily ascribed to α2 (and possibly α3) subunit activation [24], whereas α5 subunit-containing GABAA receptors appear to be involved in learning and memory [25, 26].”
BackgroundBenzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560 · cited 1×
“…(i) the GABAA receptor (subunit expression and receptor coupling), (ii) intracellular changes stemming from transcriptional and neurotrophic factors, (iii) ionotropic glutamate receptors, (iv) other neurotransmitters (serotonin, dopamine, and acetylcholine systems), and (v) the neurosteroid system.”
BackgroundGABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499 · cited 3×
“From a clinical perspective, the understanding of tolerance is important because longterm benzodiazepine treatment with continuing efficacy— using either existing or novel and more selective drugs— could offer potential benefits to several groups of patients.”
BackgroundExtrasynaptic GABA A Receptors: Form, Pharmacology, and Function
Belelli, D., Harrison, N. L., Maguire, J., Macdonald, R. L., Walker, M. C., & Cope, D. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3340-09.2009 · Cited by 464 · cited 1×
“Then, the putative molecular mechanisms underlying benzodiazepine tolerance will be extensively discussed, followed by a section specifically addressing the issue of tolerance development with novel and more selective benzodiazepines in the light of the putative tolerance mechanisms associated with…”
BackgroundReversal of pathological pain through specific spinal GABAA receptor subtypes
Knabl, J., Witschi, R., Hösl, K., Reinold, H., Zeilhofer, U. B., Ahmadi, S., Brockhaus, J., Sergejeva, M., Hess, A., Brune, K., et al. (2008) · Nature · doi:10.1038/nature06493 · Cited by 438
Neural bases for addictive properties of benzodiazepines
Tan, K. R., Brown, M., Labouèbe, G., Yvon, C., Creton, C., Fritschy, J.-M., Rudolph, U., & Lüscher, C. (2010) · Nature · doi:10.1038/nature08758 · Cited by 397 · cited 1×
“Importantly, there is no convincing evidence that tolerance occurs with α subunit subtypeselective compounds acting at the benzodiazepine site.”
BackgroundInhibition of GABAASynaptic Responses by Brain-Derived Neurotrophic Factor (BDNF) in Rat Hippocampus
Tanaka, T., Saito, H., & Matsuki, N. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-09-02959.1997 · Cited by 385
Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis
Barker, M. (2004) · Archives of Clinical Neuropsychology · doi:10.1016/s0887-6177(03)00096-9 · Cited by 307
Kittler, J. T., & Moss, S. J. (2003) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(03)00064-3 · Cited by 301 · cited 1×
“To our knowledge, no studies exist which have directly investigated GABAA receptor subunit composition after chronic exposure.”
BackgroundLewis, D. A., Cho, R. Y., Carter, C. S., Eklund, K., Forster, S., Kelly, M. A., & Montrose, D. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030395 · Cited by 292 · cited 1×
“Indeed, increasing knowledge on the specific functions of different GABAA receptor subunits has led to a breakthrough of novel and more selective drugs acting at the benzodiazepine site of the GABAA receptor.”
BackgroundBenzodiazepine Dependence A Review of the Evidence
Owen, R. T., & Tyrer, P. (1983) · Drugs · doi:10.2165/00003495-198325040-00003 · Cited by 287
Role of GABA and Glutamate Circuitry in Hypothalamo‐Pituitary‐Adrenocortical Stress Integration
HERMAN, J. P., MUELLER, N. K., & FIGUEIREDO, H. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1296.004 · Cited by 282 · cited 1×
“In support, close neuroanatomical connections exist between GABAergic and glutamatergic neurons [108, 109].”
BackgroundChronic benzodiazepine treatment decreases postsynaptic GABA sensitivity
Gallager, D. W., Lakoski, J. M., Gonsalves, S. F., & Rauch, S. L. (1984) · Nature · doi:10.1038/308074a0 · Cited by 280 · cited 2×
“Also, the observed uncoupling after chronic benzodiazepine treatment is rapidly reversed by a brief exposure in vivo to the benzodiazepine antagonist flumazenil [83, 86].”
BackgroundLong-term Diazepam Therapy and Clinical Outcome
Rickels, K. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1983.03340060045024 · Cited by 276
Long-term Diazepam Therapy and Clinical Outcome
Rickels, K. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.250.6.767 · Cited by 276
Jovanovic, J. N., Thomas, P., Kittler, J. T., Smart, T. G., & Moss, S. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3606-03.2004 · Cited by 273
Griffiths, R. R., & Weerts, E. M. (1997) · Psychopharmacology · doi:10.1007/s002130050422 · Cited by 260
Brünig, I., Penschuck, S., Berninger, B., Benson, J., & Fritschy, J. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01506.x · Cited by 247
The benzodiazepine withdrawal syndrome
PÉTURSSON, H. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03743.x · Cited by 246 · cited 1×
“Despite decades of basic and clinical research, our understanding of how benzodiazepines tend to lose their efficacy over time (tolerance) is at least incomplete.”
BackgroundBenzodiazepines in the Treatment of Epilepsy A Review
BROWNE, T. R., & PENRY, J. K. (1973) · Epilepsia · doi:10.1111/j.1528-1157.1973.tb03965.x · Cited by 241 · cited 1×
“The use of benzodiazepines over a longer period of time in epilepsy is limited due to the development of tolerance [52].”
BackgroundAn Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition
Dawson, G. R., Maubach, K. A., Collinson, N., Cobain, M., Everitt, B. J., MacLeod, A. M., Choudhury, H. I., McDonald, L. M., Pillai, G., Rycroft, W., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092320 · Cited by 241 · cited 1×
“From a clinical perspective, the understanding of tolerance is important because longterm benzodiazepine treatment with continuing efficacy— using either existing or novel and more selective drugs— could offer potential benefits to several groups of patients.”
BackgroundBasic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal
Bateson, A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396681 · Cited by 240 · cited 2×
“Decades of research into the molecular effects of long-term benzodiazepine treatment have already importantly advanced our understanding of tolerance and several excellent reviews on this topic have already been published [5, 11, 34, 77].”
BackgroundArmstrong, N., Jasti, J., Beich-Frandsen, M., & Gouaux, E. (2006) · Cell · doi:10.1016/j.cell.2006.08.037 · Cited by 220 · cited 1×
“Relevant to this review, a study showed that AMPA receptor desensitization was caused by a rupture of a domain interface which allowed the ion channel to close, providing a simple yet elegant explanation [117].”
BackgroundLERMA, J. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.08.004 · Cited by 213 · cited 1×
“subunits and can be arranged in different ways to form a functional tetramer (for review, see [118]).”
BackgroundRegulation of GABAA Receptor Subunit Expression by Pharmacological Agents
Uusi-Oukari, M., & Korpi, E. R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002063 · Cited by 213
Rowlett, J. K., Platt, D. M., Lelas, S., Atack, J. R., & Dawson, G. R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405621102 · Cited by 212 · cited 2×
“In any case, the α5 subunit may not be directly involved in the abuse potential of classical benzodiazepines as the α1-preferring hypnotic zolpidem with no affinity for the α5 subunit still led to selfadministration in primates [30].”
BackgroundFeng, J., Cai, X., Zhao, J., & Yan, Z. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06502.2001 · Cited by 212 · cited 2×
“For example, the receptor for activated C kinase (RACK-1) potentiated PKC-dependent phosphorylation of GABAA receptors mediated by the activation of muscarinic acetylcholine receptors [145], and serotonergic neurotransmission inhibited GABAergic signaling via GABAA receptor PKC-dependent phosphorylation, again with in…”
BackgroundNeurosteroid modulation of synaptic and extrasynaptic GABAA receptors
Herd, M. B., Belelli, D., & Lambert, J. J. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.007 · Cited by 206
Tolerance to the behavioral actions of benzodiazepines
File, S. E. (1985) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(85)90037-5 · Cited by 205
Bolton, M. M., Pittman, A. J., & Lo, D. C. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-09-03221.2000 · Cited by 201 · cited 1×
“In support, BDNF (and NT-4) was found to acutely reduce postsynaptic GABAA receptor immunoreactivity via activation of TrkB receptors [135–139], even though one study reported an increase [140], and another study reports that chronic BDNF treatment potentiates GABAergic inhibition [141].”
BackgroundRebound Insomnia: A New Clinical Syndrome
Kales, A., Scharf, M. B., & Kales, J. D. (1978) · Science · doi:10.1126/science.684426 · Cited by 200 · cited 1×
“Oral administration of triazolam, a short acting benzodiazepine, initially improved both sleep induction and maintenance, but latency to sleep and the number of awakenings were back to baseline values after two weeks of triazolam use [42].”
BackgroundKrystal, J. H., Staley, J., Mason, G., Petrakis, I. L., Kaufman, J., Harris, R. A., Gelernter, J., & Lappalainen, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.9.957 · Cited by 198
Abuse and dependence liability of benzodiazepine-type drugs: GABAA receptor modulation and beyond
Licata, S. C., & Rowlett, J. K. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.01.001 · Cited by 197 · cited 1×
“Importantly, there is no convincing evidence that tolerance occurs with α subunit subtypeselective compounds acting at the benzodiazepine site.”
BackgroundModulation of Synaptic GABAAReceptor Function by PKA and PKC in Adult Hippocampal Neurons
Poisbeau, P., Cheney, M. C., Browning, M. D., & Mody, I. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-02-00674.1999 · Cited by 190
CURRAN, H. V., COLLINS, R., FLETCHER, S., KEE, S. C. Y., WOODS, B., & ILIFFE, S. (2003) · Psychological Medicine · doi:10.1017/s0033291703008213 · Cited by 190 · cited 1×
“In support, in human subjects, discontinuation of benzodiazepines did not decrease sleep quality compared to a group that stayed on benzodiazepines up to 52 weeks after cessation [50], or even increased sleep quality and slow wave sleep after discontinuation in insomnia patients [51].”
BackgroundAtack, J. R., Wafford, K. A., Tye, S. J., Cook, S. M., Sohal, B., Pike, A., Sur, C., Melillo, D., Bristow, L., Bromidge, F., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089920 · Cited by 188 · cited 2×
“Similarly, chronic treatment with TPA023 (partial agonist at α2GABAA, α3GABAA, and α5GABAA receptors) also did not result in FG-7142-induced seizures in mice [156].”
BackgroundChronic use of benzodiazepines and psychomotor and cognitive test performance
Lucki, I., Rickels, K., & Geller, A. (1986) · Psychopharmacology · doi:10.1007/bf00178503 · Cited by 186 · cited 1×
“Most studies have found continued short-term memory impairment after acute administration of benzodiazepines in chronically treated subjects [38, 39, 61].”
BackgroundNeurosteroids: Endogenous allosteric modulators of GABAA receptors
Lambert, J. J., Cooper, M. A., Simmons, R. D. J., Weir, C. J., & Belelli, D. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.08.009 · Cited by 180
Otto, M. W., Pollack, M. H., Gould, R. A., Worthington, J. J., McArdle, E. T., Rosenbaum, J. F., & Heimberg, R. G. (2000) · Journal of Anxiety Disorders · doi:10.1016/s0887-6185(00)00027-x · Cited by 175
Synaptic and nonsynaptic localization of GABAAreceptors containing the α5 subunit in the rat brain
Serwanski, D. R., Miralles, C. P., Christie, S. B., Mehta, A. K., Li, X., & De Blas, A. L. (2006) · Journal of Comparative Neurology · doi:10.1002/cne.21115 · Cited by 164 · cited 1×
“…mechanisms underlying benzodiazepine tolerance will be extensively discussed, followed by a section specifically addressing the issue of tolerance development with novel and more selective benzodiazepines in the light of the putative tolerance mechanisms associated with classical benzodiazepines.”
BackgroundLiang, J., Zhang, N., Cagetti, E., Houser, C. R., Olsen, R. W., & Spigelman, I. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4702-05.2006 · Cited by 161
Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence
Allison, C., & Pratt, J. A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00029-9 · Cited by 160 · cited 2×
“Importantly, there is no convincing evidence that tolerance occurs with α subunit subtypeselective compounds acting at the benzodiazepine site.”
BackgroundDopamine D4Receptors Modulate GABAergic Signaling in Pyramidal Neurons of Prefrontal Cortex
Wang, X., Zhong, P., & Yan, Z. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09185.2002 · Cited by 155
GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence?
Wafford, K. A. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.006 · Cited by 154 · cited 1×
“Importantly, there is no convincing evidence that tolerance occurs with α subunit subtypeselective compounds acting at the benzodiazepine site.”
BackgroundSoldatos, C. R., Dikeos, D. G., & Whitehead, A. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199909000-00004 · Cited by 154 · cited 1×
“However, this may be an overgeneralization, as a review showed that tolerance in human subjects only marginally emerged after chronic treatment with the short-acting drugs midazolam and zolpidem, even though the short-acting drug triazolam was associated with tolerance [48].”
Backgroundvan Rijnsoever, C., Täuber, M., Choulli, M. K., Keist, R., Rudolph, U., Mohler, H., Fritschy, J. M., & Crestani, F. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1067-04.2004 · Cited by 144 · cited 1×
“From a clinical perspective, the understanding of tolerance is important because longterm benzodiazepine treatment with continuing efficacy— using either existing or novel and more selective drugs— could offer potential benefits to several groups of patients.”
BackgroundEarly Morning Insomnia with Rapidly Eliminated Benzodiazepines
Kales, A., Soldatos, C. R., Bixler, E. O., & Kales, J. D. (1983) · Science · doi:10.1126/science.6131538 · Cited by 138 · cited 1×
“Importantly, early-morning insomnia associated with shortacting benzodiazepines triazolam and midazolam markedly worsened after 7 days of treatment [43].”
BackgroundGABAA Receptor Subtype-Selective Modulators. I. α2/α3-Selective Agonists as Non-Sedating Anxiolytics
R. Atack, J. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795371350 · Cited by 132
History of benzodiazepine dependence
LADER, M. H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90027-8 · Cited by 129 · cited 3×
“Mechanism 2: Alterations in GABAA Receptor Subunit Expression.”
BackgroundInfluentialBenes, F. M., Todtenkopf, M. S., Logiotatos, P., & Williams, M. (2000) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(00)00105-8 · Cited by 123 · cited 1×
“In contrast to the localization of GAD67 in the neuronal body, GAD65 is primarily expressed in axon terminals, suggesting a role for GAD65 in synaptic neurotransmission and a more general role for GAD67 in regulating GABA synthesis [32].”
BackgroundSchweizer, E. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820130053009 · Cited by 120 · cited 1×
“In patients with panic disorder, neither anxiolytic tolerance nor daily dose increase was observed after 8 weeks of alprazolam treatment with continued efficacy [67].”
BackgroundGlutamate receptor dynamics and protein interaction: Lessons from the NMDA receptor
Bard, L., & Groc, L. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.05.009 · Cited by 120 · cited 1×
“Functional NMDA receptors contain two obligatory GluN1 and two regulatory GluN2/3 subunits and are vital for synaptic plasticity (for review, see [114]).”
BackgroundLong-term treatment of social phobia with clonazepam.
Davidson, J. R., Ford, S. M., Smith, R. D., & Potts, N. L. S. (1991) · PubMed · Cited by 116
Griffiths, R. R., Sannerud, C. A., Ator, N. A., & Brady, J. V. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11429-8 · Cited by 112 · cited 1×
“From a clinical perspective, the understanding of tolerance is important because longterm benzodiazepine treatment with continuing efficacy— using either existing or novel and more selective drugs— could offer potential benefits to several groups of patients.”
BackgroundLack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem.
Perrault, G., Morel, E., Sanger, D. J., & Zivkovic, B. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10339-x · Cited by 110
Brandon, N. J., Jovanovic, J. N., Smart, T. G., & Moss, S. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06353.2002 · Cited by 106 · cited 1×
“For example, the receptor for activated C kinase (RACK-1) potentiated PKC-dependent phosphorylation of GABAA receptors mediated by the activation of muscarinic acetylcholine receptors [145], and serotonergic neurotransmission inhibited GABAergic signaling via GABAA receptor PKC-dependent phosphorylation, again with in…”
BackgroundWhy low‐dose benzodiazepine‐dependent insomniacs can't escape their sleeping pills
Schneider‐Helmert, D. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb06408.x · Cited by 104 · cited 1×
“A study in low-dose benzodiazepine-dependent subjects showed a complete loss of hypnotic activity independent of the half-life of the prescribed benzodiazepine, even though a substantial suppression of REM sleep still occurred [37].”
BackgroundLack of Relationship Between Long-Term Use of Benzodiazepines and Escalation to High Dosages
Soumerai, S. B., Simoni-Wastila, L., Singer, C., Mah, C., Gao, X., Salzman, C., & Ross-Degnan, D. (2003) · Psychiatric Services · doi:10.1176/appi.ps.54.7.1006 · Cited by 104 · cited 1×
“In clinical practice, the majority of patients do not escalate their dose, suggesting that drug reinforcement tolerance may not emerge [80].”
BackgroundDiazepam dependence prevented by glutamate antagonists.
Steppuhn, K. G., & Turski, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6889 · Cited by 101
The history of benzodiazepine dependence: A review of animal studies
File, S. E. (1990) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80214-3 · Cited by 101
Established anticonvulsants and treatment of refractory epilepsy
Brodie, M. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91886-f · Cited by 100
Yan, Z. (2002) · Molecular Neurobiology · doi:10.1385/mn:26:2-3:203 · Cited by 100
Roca, D. J., Rozenberg, I., Farrant, M., & Farb, D. H. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09947-x · Cited by 98
Comparative Tolerability of Newer Agents for Insomnia
Zammit, G. (2009) · Drug Safety · doi:10.2165/11312920-000000000-00000 · Cited by 98 · cited 1×
“hypothesis, ligands that do not bind to the α5 subunit such as zolpidem have a reduced tendency to engender tolerance [158, 159], supported by studies in which chronic treatment with zolpidem (but not midazolam) did not produce any tolerance to sedative and anticonvulsant effects in mice and rats [160–162].”
ResultLack of cognitive recovery following withdrawal from long-term benzodiazepine use
Tata, P. R., Rollings, J., Collins, M., Pickering, A., & Jacobson, R. R. (1994) · Psychological Medicine · doi:10.1017/s0033291700026969 · Cited by 97 · cited 1×
“A major concern is that loss of memory associated with benzodiazepine use may be lasting, even after treatment discontinuation [62, 63], although other studies reported improved cognitive functioning after discontinuation with increased speed and accuracy of information processing, improved reaction time and working m…”
ResultGABA transporters as drug targets for modulation of GABAergic activity
Schousboe, A., Sarup, A., Larsson, O. M., & White, H. S. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.06.041 · Cited by 96 · cited 1×
“In situ hybridization and immunohistochemical studies have shown that GABAA receptor subunits display a distinct CNS distribution with a differential cellular localization pattern, suggesting that GABAA receptor subunits have a specialized function (Table 1) [14].”
BackgroundIntracellular trafficking of GABAA receptors
Barnes, E. M. (2000) · Life Sciences · doi:10.1016/s0024-3205(99)00469-5 · Cited by 94 · cited 1×
“Another interesting suggestion is that a possible loss of synaptic function after chronic exposure could be due to a shift to a perisynaptic or even an extrasynaptic localization of GABAA receptors, away from clustering of GABAA receptors at synapses (Figure 2) [106].”
BackgroundChronic benzodiazepine usage and withdrawal in insomnia patients
Poyares, D., Guilleminault, C., Ohayon, M. M., & Tufik, S. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.10.003 · Cited by 94 · cited 1×
“In support, in human subjects, discontinuation of benzodiazepines did not decrease sleep quality compared to a group that stayed on benzodiazepines up to 52 weeks after cessation [50], or even increased sleep quality and slow wave sleep after discontinuation in insomnia patients [51].”
BackgroundIzzo, E., Auta, J., Impagnatiello, F., Pesold, C., Guidotti, A., & Costa, E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051628698 · Cited by 90 · cited 1×
“However, glutamate receptor mRNA and protein changes may be dynamic during withdrawal, with unchanged levels during the early phase of withdrawal but changes occurring several days later [112].”
BackgroundHenneberger, C., Jüttner, R., Rothe, T., & Grantyn, R. (2002) · Journal of Neurophysiology · doi:10.1152/jn.2002.88.2.595 · Cited by 87 · cited 1×
“phosphorylation, decreased subunit synthesis, or increased postsynaptic receptor internalization or diffusion [139].”
BackgroundBenzodiazepine Sensitivity in Panic Disorder: Effects of Chronic Alprazolam Treatment
Cowley, D. S., Roy-Byrne, P. P., Radant, A., Ritchie, J. C., Greenblatt, D. J., Nemeroff, C. B., & Hommer, D. W. (1995) · Neuropsychopharmacology · doi:10.1038/sj.npp.1380249 · Cited by 87 · cited 3×
“However, another study reported tolerance to the acute amnesic effects of alprazolam after chronic use [40].”
BackgroundInfluentialThe Biochemistry, Ultrastructure, and Subunit Assembly Mechanism of AMPA Receptors
Nakagawa, T. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8149-x · Cited by 83 · cited 1×
“AMPA receptors are widespread heterotetrameric ligand-gated ion channels composed of four types of subunits (GluR1–4), and are crucial to long-term synaptic plasticity such as long-term potentiation (for review see [116]).”
BackgroundRegulation of GABAA receptor membrane trafficking and synaptic localization
Arancibia‐Cárcamo, I. L., & Kittler, J. T. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.012 · Cited by 76
Cheng, Q., & Yeh, H. H. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2002.037846 · Cited by 73
Tietz, E. I., Chiu, T. H., & Rosenberg, H. C. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90747-4 · Cited by 72
Clonazepam in the Treatment of Panic Disorder and Agoraphobia: A One-Year Follow-up
POLLACK, M. H., TESAR, G. E., ROSENBAUM, J. F., & SPIER, S. A. (1986) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198610000-00010 · Cited by 70
Friedman, L. K., Gibbs, T. T., & Farb, D. H. (1996) · Brain Research · doi:10.1016/0006-8993(95)01226-5 · Cited by 69
Little, H. J., Nutt, D., & Taylor, S. C. (1987) · Brain Research Bulletin · doi:10.1016/0361-9230(87)90106-7 · Cited by 69 · cited 1×
“Binding studies also generally report no changes in benzodiazepine binding after chronic treatment [92, 93, 104].”
BackgroundA glutamatergic hypothesis of drug dependence: extrapolations from benzodiazepine receptor ligands
Stephens, D. N. (1995) · Behavioural Pharmacology · doi:10.1097/00008877-199508000-00004 · Cited by 68 · cited 2×
“Several studies have addressed the compensatory glutamate sensitization hypothesis during chronic benzodiazepine exposure to account for the development of tolerance (as reviewed by [5, 110]).”
BackgroundDizocilpine prevents the development of tolerance to the sedative effects of diazepam in rats
File, S. E., & Fernandes, C. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90282-8 · Cited by 68
Ali, N. J., & Olsen, R. W. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00664.x · Cited by 67
Ator, N. A., Atack, J. R., Hargreaves, R. J., Burns, H. D., & Dawson, G. R. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158303 · Cited by 66 · cited 2×
“Importantly, there is no convincing evidence that tolerance occurs with α subunit subtypeselective compounds acting at the benzodiazepine site.”
BackgroundGonsalves, S. F., & Gallager, D. W. (1987) · Brain Research · doi:10.1016/0006-8993(87)90993-0 · Cited by 65
Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam.
Charney, D. S., & Woods, S. W. (1989) · PubMed · Cited by 62
Sleep Laboratory Studies of Hypnotic Drugs: Efficacy and Withdrawal Effects
KALES, A., & KALES, J. D. (1983) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198304000-00038 · Cited by 61 · cited 1×
“Flurazepam, which has a relatively long elimination half-life, was shown to be effective for initiating and maintaining sleep with intermediate and long-term use (over 4 weeks), even though daytime sedation diminished during prolonged use [47].”
BackgroundPrimus, R. J., Yu, J., Xu, J., Hartnett, C., Meyyappan, M., Kostas, C., Ramabhadran, T. V., & Gallager, D. W. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12410-5 · Cited by 60 · cited 2×
“Also, the observed uncoupling after chronic benzodiazepine treatment is rapidly reversed by a brief exposure in vivo to the benzodiazepine antagonist flumazenil [83, 86].”
BackgroundHYPNOTIC EFFICACY OF TEMAZEPAM: A LONG‐TERM SLEEP LABORATORY EVALUATION
MITLER, M. M., CARSKADON, M. A., PHILLIPS, R. L., STERLING, W. R., ZARCONE, V. P., SPIEGEL, R., GUILLEMINAULT, C., & DEMENT, W. C. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb00459.x · Cited by 60 · cited 1×
“or 54 nights in 7-8 subjects with chronic insomnia found no development of drug tolerance due to long-term temazepam administration [46].”
BackgroundIntermediate Use of Triazolam: A Sleep Laboratory Study
Roth, T., Kramer, M., & Lutz, T. (1976) · Journal of International Medical Research · doi:10.1177/030006057600400109 · Cited by 60 · cited 1×
“However, conflicting studies with triazolam exist that did not show any tolerance development [44, 45].”
BackgroundUsami, N., Yamamoto, T., Shintani, S., Higaki, Y., Ishikura, S., Patagiri, Y., & Hara, A. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.441 · Cited by 59 · cited 1×
“In light of the plasticity-inducing actions of neurosteroids on inhibitory signaling, long-term enhancement of the GABA system with benzodiazepines may in turn evoke changes in the neurosteroids system such as changes in neurosteroid synthesis and metabolism, although classical benzodiazepines may differ in their pote…”
BackgroundMizoguchi, Y., Kanematsu, T., Hirata, M., & Nabekura, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305872200 · Cited by 59
Ator, N. A. (2005) · CNS Spectrums · doi:10.1017/s1092852900009883 · Cited by 59 · cited 1×
“Using self-administration studies, it was shown that efficacy at α1-containing GABAA subtypes significantly contributed to the reinforcing effects and withdrawal symptoms of benzodiazepines [8, 28, 29].”
BackgroundGriebel, G., Perrault, G., Simiand, J., Cohen, C., Granger, P., Decobert, M., Françon, D., Avenet, P., Depoortere, H., Tan, S., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29437-4 · Cited by 59
Diazepam‐induced adaptive plasticity revealed by α1 GABAA receptor‐specific expression profiling
Huopaniemi, L., Keist, R., Randolph, A., Certa, U., & Rudolph, U. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02216.x · Cited by 58 · cited 1×
“Using a point mutation genetic approach, transcriptional reduction was found in calcium-/calmodulin-dependent kinase IIα and MAP kinase phosphatase-1in control mice but not in α1(H101R) after acute administration of diazepam [98].”
BackgroundThe impact of sedative-hypnotic use on sleep symptoms in elderly nursing home residents*
Monane, M., Glynn, R. J., & Avorn, J. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90027-2 · Cited by 56 · cited 1×
“Another issue is that convincing evidence for improved sleep after long-term use is lacking [49], yet this may not be the sole result of tolerance but could also be attributable to a generalized lack of efficacy.”
BackgroundCurran, H. V., Bond, A., O'Sullivan, G., Bruce, M., Marks, I., Lelliot, P., Shine, P., & Lader, M. (1994) · Psychological Medicine · doi:10.1017/s0033291700029056 · Cited by 54 · cited 1×
“Most studies have found continued short-term memory impairment after acute administration of benzodiazepines in chronically treated subjects [38, 39, 61].”
BackgroundTehrani, M. H. J., & Barnes, E. M. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37019-3 · Cited by 53
Atack, J. R. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57004-9 · Cited by 52
Rundfeldt, C., Wlaź, P., Hönack, D., & Löscher, W. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12118-6 · Cited by 52 · cited 2×
“However, interpretations should be made with caution since chronic treatment with nonselective partial positive allosteric modulators such as bretazenil did neither result in anticonvulsant tolerance [54, 59, 60] nor in FG-7142-precipitated seizures [155].”
BackgroundResultAllen, D., Curran, H. V., & Lader, M. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00265843 · Cited by 51 · cited 2×
“Moreover, tolerance to benzodiazepine-induced decreased reaction speed was shown after 10 days of alprazolam treatment [41].”
BackgroundReddy, D. S., & Kulkarni, S. K. (1997) · PubMed · Cited by 49
Rickels, K., Lucki, I., Schweizer, E., Garcia-Espana, F., & Case, W. G. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199904000-00003 · Cited by 49
Lyons, H. R., Land, M. B., Gibbs, T. T., & Farb, D. H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00501.x · Cited by 48 · cited 1×
“In addition, changes in intracellularly located cAMP-response-element-binding protein (CREB) or calcium, vital in various second messenger systems, could be altered, and prolonged GABA concentrations in a neuronal culture have been shown to affect voltage-gated calcium channels [133].”
BackgroundTehrani, M. H. J., & Barnes, E. M. (1997) · PubMed · Cited by 48
Investigation of the development of tolerance to the actions of zolpidem and midazolam
Sanger, D. J., & Zivkovic, B. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90172-9 · Cited by 47
Benzodiazepine Dependence: From Neural Circuits to Gene Expression
Pratt, J. A., Brett, R. R., & Laurie, D. J. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00539-x · Cited by 47 · cited 1×
“…of this evidence, we review the current evidence for the neuroadaptive mechanisms underlying benzodiazepine tolerance, including changes of (i) the GABAA receptor (subunit expression and receptor coupling), (ii) intracellular changes stemming from transcriptional and neurotrophic factors,…”
BackgroundMierlak, D., & Farb, D. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-03-00814.1988 · Cited by 46 · cited 1×
“In support, uncoupling seems to develop rapidly, with the classical benzodiazepine chlordiazepoxide (applied together with GABA) stimulating the rate and extent of desensitization produced in a single neuron within several seconds [99].”
BackgroundHewitt, S. A., & Bains, J. S. (2006) · Journal of Neurophysiology · doi:10.1152/jn.01135.2005 · Cited by 46 · cited 1×
“This reduced immunoreactivity was hypothesized to be caused by a reduction in GABAA receptor surface expression and was accompanied by reduced postsynaptic responses with the direct GABAA receptor agonist muscimol [142].”
BackgroundSanger, D. (1992) · Neuropharmacology · doi:10.1016/0028-3908(92)90148-i · Cited by 44
Klein, R. L., & Harris, R. A. (1996) · Japanese Journal of Pharmacology · doi:10.1254/jjp.70.1 · Cited by 41
Hegarty, A. A., & Vogel, W. H. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00177-x · Cited by 40 · cited 1×
“In contrast, only acute but not chronic diazepam treatment decreased basal extracellular dopamine levels in rats, even though both acute and chronic treatment regimens could reverse the stress-induced rise of cortical dopamine levels [149].”
BackgroundTönne, U., Hiltunen, A. J., Vikander, B., Engelbrektsson, K., Bergman, H., Bergman, I., Leifman, H., & Borg, S. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb09786.x · Cited by 40
Klein, R. L., Mascia, M. P., Harkness, P. C., Hadingham, K. L., Whiting, P. J., & Harris, R. A. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10707-6 · Cited by 40
Altered γ-aminobutyric acid/benzodiazepine interaction after chronic diazepam exposure
Heninger, C. (1988) · Neuropharmacology · doi:10.1016/0028-3908(88)90070-6 · Cited by 38 · cited 1×
“Binding studies also generally report no changes in benzodiazepine binding after chronic treatment [92, 93, 104].”
BackgroundMirza, N. R., & Nielsen, E. Ø. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.094474 · Cited by 38 · cited 5×
“In support, subchronic treatment with different classical benzodiazepines lead to differential propensity for FG7142-induced seizures in mice, with triazolam, clonazepam, and diazepam producing around seizures in around 80% of the mice, whereas alprazolam and midazolam did so in 60% of the animals and lorazepam in 40%…”
BackgroundInfluentialLöscher, W., Rundfeldt, C., Hönack, D., & Ebert, U. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21163-6 · Cited by 37
Tsunoda, K., Uchida, H., Suzuki, T., Watanabe, K., Yamashima, T., & Kashima, H. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2465 · Cited by 37
Wong, G., Lyon, T., & Skolnick, P. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09851-7 · Cited by 36
Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons
Ator, N. A. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00123-x · Cited by 35 · cited 1×
“Circumstantial evidence stems from the fact that α1-preferential affinity-selective compounds such as zolpidem produce physical dependence [165], even though the compound TPA123 that possesses 23% efficacy at the α1 subunit (but is not affinity selective) did also result in physical dependence [8].”
BackgroundA 2-Year Follow-up of Social Phobia: Status After a Brief Medication Trial
SUTHERLAND, S. M., TUPLER, L. A., COLKET, J. T., & DAVIDSON, J. R. T. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199612000-00003 · Cited by 35
Lack of anticonvulsant tolerance with RU 32698 and Ro 17-1812
Feely, M., Boyland, P., Picardo, A., Cox, A., & Paul Gent, J. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90482-2 · Cited by 34 · cited 2×
“However, interpretations should be made with caution since chronic treatment with nonselective partial positive allosteric modulators such as bretazenil did neither result in anticonvulsant tolerance [54, 59, 60] nor in FG-7142-precipitated seizures [155].”
BackgroundResultWilson, M. A., & Biscardi, R. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90614-a · Cited by 34
Arnot, M. I., Davies, M., Martin, I. L., & Bateson, A. N. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1115 · Cited by 33
The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation
Koff, J. M., Pritchard, G. A., Greenblatt, D. J., & Miller, L. G. (2008) · Pharmacology · doi:10.1159/000139531 · Cited by 33 · cited 1×
“Also, lorazepam-induced tolerance to its acute anticonvulsant effects was partially prevented with simultaneous CPP treatment [122].”
BackgroundTsuda, M., Shimizu, N., Yajima, Y., Suzuki, T., & Misawa, M. (1998) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/pl00005172 · Cited by 33 · cited 1×
“Increases in cortical mRNA of NMDA NR1 and NR2B subunits have been reported in rats tolerant to diazepam [124, 125], which were prevented by concomitant treatment with the NMDA receptor antagonist MK-801 [126].”
BackgroundVan Sickle, B. J., Cox, A. S., Schak, K., John Greenfield, L., & Tietz, E. I. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00152-1 · Cited by 33
Weerts, E. M., & Griffiths, R. R. (1998) · PubMed · Cited by 31
Fernandes, C., File, S. E., & Berry, D. (1996) · Brain Research · doi:10.1016/0006-8993(96)00644-0 · Cited by 30 · cited 1×
“Before taking a closer look at specific mechanisms that have been proposed to underlie benzodiazepine tolerance, it is important to note that pharmacokinetic factors probably do not play a major role in the development of tolerance [81].”
BackgroundChronic Use of Triazolam: The Effects on the Sleep Patterns of Insomniacs
Pegram, V., Hyde, P., & Linton, P. (1980) · Journal of International Medical Research · doi:10.1177/030006058000800308 · Cited by 29 · cited 1×
“However, conflicting studies with triazolam exist that did not show any tolerance development [44, 45].”
BackgroundVan Sickle, B. J., & Tietz, E. I. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00065-5 · Cited by 29
The behavioral effects of benzodiazepines following long-term use.
Lucki, I., & Rickels, K. (1986) · PubMed · Cited by 29
Long‐Term Comparison of Alprazolam, Lorazepam and Placebo in Patients with an Anxiety Disorder
Cohn, J. B., & Wilcox, C. S. (1984) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1984.tb03327.x · Cited by 28 · cited 1×
“Furthermore, additional studies all show a continuing anxiolytic effect, at least for panic disorder [69– 72], generalized anxiety disorder [73], and social phobia [74– 76].”
BackgroundAllison, C., & Pratt, J. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300800 · Cited by 27 · cited 1×
“Even though the AMPA receptor antagonist GYKI 52466 did not affect the development of tolerance to the sedative effects of diazepam [121], changes in AMPA receptor subunits have been reported to be altered after long-term benzodiazepine exposure [130].”
BackgroundZolpidem tolerance and dependence —two case reports
Ravishankar, A., & Carnwath, T. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200114 · Cited by 26 · cited 1×
“hypothesis, ligands that do not bind to the α5 subunit such as zolpidem have a reduced tendency to engender tolerance [158, 159], supported by studies in which chronic treatment with zolpidem (but not midazolam) did not produce any tolerance to sedative and anticonvulsant effects in mice and rats [160–162].”
ResultBrett, R. R., & Pratt, J. A. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15083.x · Cited by 26 · cited 1×
“Binding studies also generally report no changes in benzodiazepine binding after chronic treatment [92, 93, 104].”
BackgroundFernandes, C., & File, S. E. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01160-3 · Cited by 25 · cited 2×
“However, as anxiolytic tolerance was not blocked by NMDA receptor antagonism, the NMDA system could also play a differential role in tolerance depending on the specific behavioral effects [123].”
BackgroundClorazepate in dogs: tolerance to the anticonvulsant effect and signs of physical dependence
Scherkl, R., Kurudi, D., & Frey, H.-H. (1989) · Epilepsy Research · doi:10.1016/0920-1211(89)90042-9 · Cited by 24 · cited 1×
“In support, one study demonstrated that marked withdrawal symptoms appeared upon abrupt discontinuation of chronic clorazepate treatment in dogs, even though tolerance was present to a rather limited extent [163].”
BackgroundLong-term pharmacologic treatment of panic disorder.
Ballenger, J. C. (1991) · PubMed · Cited by 24
Lilly, S. M., Zeng, X. J., & Tietz, E. I. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01746.x · Cited by 21
Peričić, D., Štrac, D. Š., Jembrek, M. J., & Vlainić, J. (2007) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-007-0152-z · Cited by 19
NMDA-NR1 and -NR2B subunits mRNA expression in the hippocampus of rats tolerant to Diazepam
Pérez, M. F., Salmirón, R., & Ramı́rez, O. A. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(03)00072-x · Cited by 19 · cited 1×
“Increases in cortical mRNA of NMDA NR1 and NR2B subunits have been reported in rats tolerant to diazepam [124, 125], which were prevented by concomitant treatment with the NMDA receptor antagonist MK-801 [126].”
BackgroundLong-term drug treatment of panic disorder
Burrows, G. D., Judd, F. K., & Norman, T. R. (1993) · Journal of Psychiatric Research · doi:10.1016/0022-3956(93)90022-t · Cited by 19
Bonavita, C. D., Bisagno, V., Bonelli, C. G., Acosta, G. B., Rubio, M. C., & Wikinski, S. I. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00012-6 · Cited by 19 · cited 1×
“Moreover, a straightforward glutamate sensitization may be an oversimplification, as tolerance to the sedative effects of lorazepam after 21-day treatment correlated with a decreased rather than an increased sensitivity for glutamate (using glutamate binding) [129].”
BackgroundAitta-aho, T., Vekovischeva, O. Y., Neuvonen, P. J., & Korpi, E. R. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.12.015 · Cited by 18 · cited 1×
“A genetic approach with GluR1 knockout mice showed that after subchronic flurazepam treatment, these mice developed a reduced and incomplete tolerance to the muscle relaxation and sedative effects of flurazepam, even though acute flurazepam effects were comparable between knockout and wild-type mice [132].”
BackgroundItier, V, Granger, P., Perrault, G., Depoortere, H., Scatton, B., & Avenet, P. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21265-4 · Cited by 16
Bonavita, C., Ferrero, A., Cereseto, M., Velardez, M., Rubio, M., & Wikinski, S. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1373-y · Cited by 16 · cited 1×
“In support, after long-term (but not acute) lorazepam treatment, no differences were found in the affinity or density of NMDA receptors, even though increased in vitro glutamate release and NMDA-induced cGMP efflux in the hippocampus was reported [128].”
BackgroundWeerts, E. M., Kaminski, B. J., & Griffiths, R. R. (1998) · Psychopharmacology · doi:10.1007/s002130050487 · Cited by 15 · cited 1×
“They concluded that tolerance to reinforcing effects of benzodiazepines appears unlikely, supported by studies in nonhuman primates in which midazolam and zolpidem maintained stable self-injection and physical dependence under conditions of chronic continuous availability [78, 79].”
ResultThe effect of diazepam on indices of 5-HT function in man
Nutt, D. J., Cowen, P. J., Franklin, M., Murdock, P., Gosden, B., & Fraser, S. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90217-0 · Cited by 14 · cited 1×
“Three weeks of diazepam treatment (25 mg/day) in healthy male volunteers resulted in tolerance to the prolactin and growth hormone response induced by the 5-HT precursor L-tryptophan, even though sedative effects of L-tryptophan remained present [147].”
BackgroundAlmirón, R. S., Pérez, M. F., & Ramı́rez, O. A. (2004) · Brain Research · doi:10.1016/j.brainres.2004.01.080 · Cited by 14 · cited 2×
“In rodents, the development of tolerance to the sedative effects of the classical benzodiazepines diazepam and chlordiazepoxide was prevented by coadministration of the NMDA receptor antagonists CPP, dizocilpine, MK-801, and ketamine [119–121].”
BackgroundEffect of NMDA antagonists on rapid tolerance to benzodiazepines
Khanna, J. M., Chau, A., & Shah, G. (1997) · Brain Research Bulletin · doi:10.1016/s0361-9230(96)00219-5 · Cited by 14
Marley, R. J., Heninger, C., Hernández, T. D., & Gallager, D. W. (1991) · Neuropharmacology · doi:10.1016/0028-3908(91)90151-z · Cited by 13 · cited 1×
“Such sensitization is reminiscent to adaptive glutamatergic processes as seen in kindling experiments, although it should be noted that kindling only occurs with intermittent and not after continuous treatment [111].”
BackgroundKhan, A., & Haleem, D. (2007) · Acta Biologica Hungarica · doi:10.1556/abiol.58.2007.4.2 · Cited by 8 · cited 1×
“Another study showed that chronic diazepam treatment resulted not only in diazepam tolerance but also in a very modest reduced efficacy of the 5-HT1A receptor agonist 8-OH-DPAT to induce flat body posture and forepaw treading [148].”
BackgroundFile, S. E., & Wilks, L. (1985) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1985.tb05054.x · Cited by 7 · cited 1×
“Chronic treatment in rodents with the α1-preferential compound CL218, 572 resulted in loss of picrotoxin-induced seizures [58].”
BackgroundLöscher, W., Rundfeldt, C., Hönack, D., & Ebert, U. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21164-8 · Cited by 7 · cited 2×
“However, interpretations should be made with caution since chronic treatment with nonselective partial positive allosteric modulators such as bretazenil did neither result in anticonvulsant tolerance [54, 59, 60] nor in FG-7142-precipitated seizures [155].”
BackgroundResult
Research works printed but not linked: 12
- 2010, Current Topics in Medicinal Chemistry, 2, 331
- 1986, Psychopharmacology Bulletin, 22, 424
- 1986, Psychopharmacology, 88, 426
- 1979, British Journal of Clinical Pharmacology, 8, 63S
- 1997, Benzodiazpines
- 1989, Journal of Clinical Psychiatry, 50, 418
- 1991, Journal of Clinical Psychiatry, 52, 18
- 1986, Journal of Clinical Psychopharmacology, 6, 302
- 1991, Journal of Clinical Psychiatry, 52, 16
- 1998, Behavioural Pharmacology, 9, 285
- 1995, Behavioural Pharmacology, 6, 425
- 1997, Methods and Findings in Experimental and Clinical Pharmacology, 19, 395
Cited by
Benzodiazepine use and risk of Alzheimer's disease: case-control study
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B. (2014) · BMJ · doi:10.1136/bmj.g5205 · Cited by 558
Benzodiazepine use and risk of dementia: prospective population based study
Billioti de Gage, S., Begaud, B., Bazin, F., Verdoux, H., Dartigues, J.-F., Peres, K., Kurth, T., & Pariente, A. (2012) · BMJ · doi:10.1136/bmj.e6231 · Cited by 436
Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.
(2018) · Europe PMC (PubMed Central) · Cited by 250
Benzodiazepine dependence and its treatment with low dose flumazenil
Hood, S. D., Norman, A., Hince, D. A., Melichar, J. K., & Hulse, G. K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12023 · Cited by 165
Association between Benzodiazepine Use and Dementia: A Meta-Analysis
Zhong, G., Wang, Y., Zhang, Y., & Zhao, Y. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127836 · Cited by 164
Metadata
- Authors
- Vinkers, C. H., & Olivier, B.
- Affiliations
- Utrecht University (NL)
- Corresponding author
- Vinkers, Christiaan H.
- Venue
- Advances in Pharmacological Sciences
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-19
- ISSN
- 1687-6334 (ISSN-L)
- 1687-6342
- PMC
- PMC3321276
- OpenAlex
- W2041124713
- Cited by
- 195
- References
- 166
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 7 · 2023: 10 · 2022: 17 · 2021: 18 · 2020: 24 · 2019: 16 · 2018: 18 · 2017: 9 · 2016: 16 · 2015: 15 · 2014: 11 · 2013: 8 · 2012: 4
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Advances in Pharmacological Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Keywords
- benzodiazepine tolerance, GABAA receptor, receptor subunit expression, receptor coupling, neural adaptation, neurotrophic factors, transcriptional regulation, ionotropic glutamate receptors, serotonin, dopamine, acetylcholine, neurosteroids, anxiolytic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.